A novel compound inhibits dengue virus, as well as other closely related important human pathogens. The research is published in the September 2011 issue of the journal Antimicrobial Agents and Chemotherapy.
Dengue virus causes an estimated about 50 million infections annually, resulting in half a million hospitalizations, and a 2.5 percent mortality rate, according to the World Health Organization (WHO). Neither antivirus therapy nor vaccines exist against dengue. The newly discovered inhibitor is also active against fellow flavivirus family members including West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus. The compound works by preventing translation of RNA to protein, according to the report.
In the study, the researchers identified the small molecule inhibitor via high throughput screening of Novartis compound libraries, says corresponding author, Pei-Yong Shi of Novartis Institute for Tropical Diseases, Singapore. They then refined the original molecule to give it greater metabolic stability. Tests in a dengue mouse viremia model showed that "this compound significantly reduced peak viremia, demonstrating the in vivo efficacy of the inhibitor," according to the report.
However, despite the fact that the compound selectively inhibits protein translation in flaviviruses, in in vitro tests, it nonselectively inhibited viral and host translation. That raised the specter of side effects, and indeed, tripling the experimental dose in the mouse model caused significant side effects, according to the report. Thus, the therapeutic window needs to be widened before the compound will be ready for clinical testing, the researchers report.
The compound is being developed under the auspices of the Novartis Institute for Tropical Diseases, which aims to develop novel therapeutics for neglected diseases, and to provide these new medicines to poor patients at cost prices," says Shi. "Dengue poses a public health threat to 2.5 billion people worldwide," most of them living in poverty or near poverty.
Reference: Q.-Y. Wang, R.R. Kondreddi, X. Xie, R. Rao, S. Nilar, H.Y. Xu, M. Quing, D. Chang, H. Dong, F. Yokokawa, S.B. Lakshminarayana, A. Goh, W. Schul, L. Kramer, T.H. Keller, and P.-Y. Shi, 2011. A translation inhibitor that suppresses dengue virus in vitro and in vivo. Antim. Agents Chemother. 55:4072-4080.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.
Broadening the Path: Diverse Educational Routes Into Infection Prevention Careers
July 4th 2025Once dominated by nurses, infection prevention now welcomes professionals from public health, lab science, and respiratory therapy—each bringing unique expertise that strengthens patient safety and IPC programs.
How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels
July 3rd 2025Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.